NovaBay Pharmaceuticals, Inc. (NBY)
| Market Cap | 4.02M |
| Revenue (ttm) | 9.78M |
| Net Income (ttm) | 2.66M |
| Shares Out | 5.82M |
| EPS (ttm) | 0.57 |
| PE Ratio | 1.52 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,014 |
| Open | 0.6450 |
| Previous Close | 0.6497 |
| Day's Range | 0.6138 - 0.7000 |
| 52-Week Range | 0.3611 - 2.4520 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 0.85 (+22.83%) |
| Earnings Date | Aug 12, 2025 |
About NBY
NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. [Read more]
Financial Performance
In 2024, NovaBay Pharmaceuticals's revenue was $9.78 million, a decrease of -6.45% compared to the previous year's $10.46 million. Losses were -$8.61 million, -48.45% less than in 2023.
Financial StatementsAnalyst Summary
According to one analyst, the rating for NBY stock is "Strong Buy" and the 12-month stock price target is $0.85.
News
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it will hold a virtual Special Meeting on April 16, 2025, at which stock...
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces the completion of the sale of its Avenova eyecare business and related a...
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Reconvened Special Meeting of Stockholders held on December 18,...
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that Chief Executive Officer Justin Hall has issued the following Letter...
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Special Meeting of Stockholders held on November 22, 2024 has b...
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the largest institutional advisory firm, Institutional Shareholder ...
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024. “Avenova sales through the on...
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) today announces that the Company has accepted a revised transaction proposal from ...
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the Company's board of directors has determined that an unsolicited...
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
This Acquisition Enhances PRN Physician Recommended Nutriceuticals' ("PRN") Product Portfolio of Science-Based Eye Health Products BLUE BELL, Pa. , Sept. 20, 2024 /PRNewswire/ -- Acumen Health Holding...
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a definitive asset purchase agreement (the “Agreemen...
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and...
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2024 and provides a business update. “Rev...
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market c...
NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova®-branded eyecare products during the Amazon Prime Day event, which was held July...
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) today announced the closing of its previously announced underwritten public offerin...
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”), today announced the pricing of its underwritten public offering of 3,200,380 share...
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces 20% discounts on Avenova®-branded eyecare products and product bundles during Amazon Prime Day being h...
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) announces preliminary net revenue for the second quarter of 2024 of $2.4 million an...
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
EMERYVILLE, Calif. & NEW YORK--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQ:...
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to custo...
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announces that the NYSE American LLC (“NYSE American”) has accepted the Company's plan to regai...
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. the “Company”) (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company's Definitive Proxy Sta...
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduct...
NovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Bruce Voss - LHA, Investor Relations Justin Hall - Chief Executive Officer and Ge...